Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:trospium
gptkb:xanomeline |
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
gptkb:N05AX
|
| gptkbp:chemicalClass |
muscarinic receptor modulator
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2023)
|
| gptkbp:developedBy |
gptkb:Karuna_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
KarXT
|
| gptkbp:indication |
schizophrenia
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
muscarinic receptor antagonist
muscarinic receptor agonist |
| gptkbp:regulates |
approved (2023)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting constipation headache abdominal discomfort dry mouth dyspepsia |
| gptkbp:targetAudience |
adults with schizophrenia
|
| gptkbp:therapeuticArea |
psychiatry
|
| gptkbp:bfsParent |
gptkb:Karuna_Therapeutics
|
| gptkbp:bfsLayer |
5
|